P0F Stock Overview
A pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Egetis Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.46 |
| 52 Week High | SEK 0.79 |
| 52 Week Low | SEK 0.32 |
| Beta | 1.43 |
| 11 Month Change | 21.29% |
| 3 Month Change | -7.70% |
| 1 Year Change | 6.09% |
| 33 Year Change | -17.29% |
| 5 Year Change | -73.45% |
| Change since IPO | -69.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| P0F | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.3% | -0.2% | 0.8% |
| 1Y | 6.1% | -16.9% | 9.1% |
Return vs Industry: P0F exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: P0F underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| P0F volatility | |
|---|---|
| P0F Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: P0F's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: P0F's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 39 | Nicklas Westerholm | www.egetis.com |
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020.
Egetis Therapeutics AB (publ) Fundamentals Summary
| P0F fundamental statistics | |
|---|---|
| Market cap | €174.59m |
| Earnings (TTM) | -€27.71m |
| Revenue (TTM) | €5.89m |
29.6x
P/S Ratio-6.3x
P/E RatioIs P0F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P0F income statement (TTM) | |
|---|---|
| Revenue | SEK 67.90m |
| Cost of Revenue | SEK 207.50m |
| Gross Profit | -SEK 139.60m |
| Other Expenses | SEK 179.70m |
| Earnings | -SEK 319.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | -0.89 |
| Gross Margin | -205.60% |
| Net Profit Margin | -470.25% |
| Debt/Equity Ratio | 34.9% |
How did P0F perform over the long term?
See historical performance and comparison